These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83 related articles for article (PubMed ID: 3504500)
41. Influence of selected surfactants on the tackiness of acrylic polymer films. Nimkulrat S; Suchiva K; Phinyocheep P; Puttipipatkhachorn S Int J Pharm; 2004 Dec; 287(1-2):27-37. PubMed ID: 15541909 [TBL] [Abstract][Full Text] [Related]
42. A comparative in vitro assessment of the drug release performance of pH-responsive polymers for ileo-colonic delivery. Ibekwe VC; Fadda HM; Parsons GE; Basit AW Int J Pharm; 2006 Feb; 308(1-2):52-60. PubMed ID: 16356670 [TBL] [Abstract][Full Text] [Related]
43. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies). National Toxicology Program Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653 [TBL] [Abstract][Full Text] [Related]
44. In vitro and in vivo evaluation of ofloxacin sustained release pellets. Cui Y; Zhang Y; Tang X Int J Pharm; 2008 Aug; 360(1-2):47-52. PubMed ID: 18538518 [TBL] [Abstract][Full Text] [Related]
45. Accelerated stability of sulphamethoxazole microcapsules coated with Eudragit RS 100 and Eudragit RL 100. Basnet S; Ganesan M; Pal TK Boll Chim Farm; 2002; 141(3):202-9. PubMed ID: 12197419 [TBL] [Abstract][Full Text] [Related]
46. Preparation of mefenamic acid sustained release beads based on kappa-carrageenan. Ozsoy Y; Bergişadi N Boll Chim Farm; 2000; 139(3):120-3. PubMed ID: 10961021 [TBL] [Abstract][Full Text] [Related]
47. Coating charcoal with polyacrylate-polymethacrylate copolymer for haemoperfusion. I: Fabrication and evaluation. Elkheshen S; Zia H; Needham TE; Badawy A; Luzzi LA J Microencapsul; 1992; 9(1):41-51. PubMed ID: 1613642 [TBL] [Abstract][Full Text] [Related]
48. Coating charcoal with polyacrylate-polymethacrylate copolymer for haemoperfusion. II. Drug removal and polymer compatibility studies. el-Kheshen S; Zia H; Needham TE; Badawi A; Luzzi LA J Microencapsul; 1994; 11(1):3-10. PubMed ID: 8138872 [TBL] [Abstract][Full Text] [Related]
49. Insights into atomic-level interaction between mefenamic acid and eudragit EPO in a supersaturated solution by high-resolution magic-angle spinning NMR spectroscopy. Higashi K; Yamamoto K; Pandey MK; Mroue KH; Moribe K; Yamamoto K; Ramamoorthy A Mol Pharm; 2014 Jan; 11(1):351-7. PubMed ID: 24283196 [TBL] [Abstract][Full Text] [Related]
50. Enteric coating of nanostructured lipid carriers (NLCs) and enteric coating of hard gelatin capsules filled with NLCs: Feasibility studies. Managuli RS; Reddy MS; Koteshwara KB; Mutalik S Pak J Pharm Sci; 2021 Jul; 34(4):1323-1331. PubMed ID: 34799304 [TBL] [Abstract][Full Text] [Related]
51. Renal ultrastructural alterations induced by various preparations of mefenamic acid. Jarrar QB; Hakim MN; Zakaria ZA; Cheema MS; Moshawih S Ultrastruct Pathol; 2020 Jan; 44(1):130-140. PubMed ID: 31967489 [TBL] [Abstract][Full Text] [Related]
52. Drug targeting using non-magnetic and magnetic albumin-globulin mix microspheres of mefenamic acid. Lalla JK; Ahuja PL J Microencapsul; 1991; 8(1):37-52. PubMed ID: 1880690 [TBL] [Abstract][Full Text] [Related]
53. [Biopharmaceutical evaluation of the rectal administration of mefenamic acid. IV. Biological availability of mefenamic acid on the base of polyoxyethylene glycol with the addition of polysorbates]. Kosior A Acta Pol Pharm; 1987; 44(1):91-5. PubMed ID: 3673627 [No Abstract] [Full Text] [Related]
54. Preparation of core particles for aqueous film coating using agitation fluidized bed. Watano S; Ando K; Miyanami K; Ii Y; Sasatani S Chem Pharm Bull (Tokyo); 1997 Dec; 45(12):2039-42. PubMed ID: 9433775 [TBL] [Abstract][Full Text] [Related]
55. Comparative ultrastructural hepatic alterations induced by free and liposome-encapsulated mefenamic acid. Jarrar QB; Hakim MN; Cheema MS; Zakaria ZA Ultrastruct Pathol; 2017; 41(5):335-345. PubMed ID: 28829237 [TBL] [Abstract][Full Text] [Related]
56. A new approach to encapsulating nonsteroidal anti-inflammatory drugs. IV. Effect of cellulose derivatives with different functional groups on the bioavailability and gastric ulcerogenic activity of acidic as well as basic nonsteroidal anti-inflammatory drugs. Meshali MM; el-Dien EZ; Omar SA; Luzzi LA J Microencapsul; 1989; 6(3):355-60. PubMed ID: 2569511 [TBL] [Abstract][Full Text] [Related]
57. Effects of food on absorption of mefenamic acid from two commercial capsules differing in bioavailability under the fasting state. Hamaguchi T; Shinkuma D; Yamanaka Y; Mizuno N J Pharmacobiodyn; 1987 Jan; 10(1):21-5. PubMed ID: 3585692 [TBL] [Abstract][Full Text] [Related]
58. A new approach to encapsulating non-steroidal anti-inflammatory drugs. V. Biopharmaceutical study of microcapsules of azapropazone coated with pectin and rutin. Meshali MM; el-Dien EZ; Omar SA; Luzzi LA J Microencapsul; 1992; 9(1):67-72. PubMed ID: 1613645 [TBL] [Abstract][Full Text] [Related]
59. Preparation and evaluation of Eudragit gels. IV: Rectal gel preparations for sustained release and avoidance of first-pass metabolism of propentofylline. Kim NS; Ito T; Kawata M; Uchida T; Goto S J Pharm Sci; 1992 Sep; 81(9):904-7. PubMed ID: 1432638 [TBL] [Abstract][Full Text] [Related]
60. [Biopharmaceutical evaluation of the rectal application of mefenamic acid. I. Study of the suppositories prepared on hydrophilic bases]. Kosiar A Acta Pol Pharm; 1983; 40(1):105-9. PubMed ID: 6880815 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]